Trial Site Detail
Drug: |
SF1126 |
|||
|---|---|---|---|---|
Trial: |
A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors |
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Ongoing, but not recruiting |
|||
Arizona Cancer Center1515 North Campbell Avenue |
Principal Investigator: |
Daruka Mahadevan, MD, PhD |
|---|---|
Contact: |
Diane Rensvold, RN 520-694-9055 drensvold@azcc.arizona.edu Judy Safarewitz, RN 520-694-9058 jsafarewitz@azcc.arizona.edu |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Arizona Cancer Center Website: |
http://oncore.azcc.arizona.edu/sip/SIPControlServlet |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.